What should be monitored during tazemetostat therapy?

Monitoring during tazemetostat therapy is crucial due to the potential side effects and interactions associated with its use. The correct answer highlights the importance of keeping track of the complete blood count, transaminases, and triglycerides for several reasons.

The complete blood count is important because tazemetostat can cause hematological issues, including cytopenias. Regular monitoring helps in early detection and management of any blood-related side effects.

Transaminases, which include alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are monitored because tazemetostat can potentially lead to liver enzyme elevations, indicating hepatotoxicity. Regular assessment helps ensure liver function remains within safe limits, allowing for timely interventions if abnormalities arise.

Monitoring triglycerides is also essential due to the association of certain medications with lipid abnormalities. Tazemetostat therapy may lead to changes in triglyceride levels, and tracking these can help manage cardiovascular risk.

In contrast, the other options suggest monitoring parameters that either do not have a direct relationship with tazemetostat therapy or may not be the primary focus in terms of safety and efficacy. Therefore, focusing on the complete blood count, transaminases, and triglycerides provides a comprehensive approach to patient